Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23244679 | 0.96 | CA2 (0.51) | CA2CA1MAPK14FOLH1EPHX2 | |
| SCHEMBL23244681 | 0.96 | CA2 (0.51) | CA2CA1MAPK14FOLH1EPHX2 | |
| SCHEMBL23244680 | 0.96 | CA2 (0.51) | CA2CA1MAPK14FOLH1EPHX2 | |
| SCHEMBL28502970 | 0.88 | CA2 (0.65) | CA2CA1KDM4EKMT2ACA12 | |
| SCHEMBL25280861 | 0.84 | NPC1 (0.48) | CA2CA1MAPK14FOLH1MAPK1 | |
| SCHEMBL25280862 | 0.84 | NPC1 (0.48) | CA2CA1MAPK14FOLH1MAPK1 | |
| SCHEMBL2236683 | 0.83 | EPHX2 (0.57) | CA2CA1EPHX2KDM4EKMT2A | |
| SCHEMBL2236675 | 0.83 | EPHX2 (0.57) | CA2CA1EPHX2KDM4EKMT2A | |
| SCHEMBL19746273 | 0.82 | CASR (0.48) | CA2CA1 | |
| SCHEMBL19746272 | 0.82 | CASR (0.48) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241615-A1 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | UNIVERSITY OF ROCHESTER | 2019-08-08 | — | — | US | disclosed |
| EP-3475294-A1 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | The University of Rochester (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223207-A1 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | UNIVERSITY OF ROCHESTER (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241615-A1 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | SHH, SMO, DACH1 | CA2 2173/4885CA1 996/4885MAPK14 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.